PharmacoEconomics & Outcomes News 792, p21 - 2 Dec 2017 Nivolumab not cost effective for head and neck cancer Nivolumab does not appear to be cost effective for the treatment of recurrent or metastatic head and neck cancer (HNC), according to findings of a US study published in the Journal of the National Cancer Institute. A Markov model populated with data from the CheckMate 141 trial was used to evaluate the cost effectiveness of nivolumab compared with standard single-agent therapy in patients with platinum-resistant, recurrent or metastatic squamous cell head and neck cancer, from a US healthcare payer perspective over a 30-year time horizon. Cost effectiveness was evaluated from a societal perspective in the sensitivity analysis. Nivolumab was estimated to gain 0.400 additional QALYs compared with standard therapy at an incremental cost of $117 800, resulting in an incremental cost-effectiveness ratio (ICER) of $294 400 per QALY gained, which greatly exceeded the willingness-to-pay threshold of $100 000 per QALY gained. The cost-effectiveness model was sensitive to the cost of nivolumab; treatment was estimated to become cost effective if the drug cost was reduced by 71%, from $13 432 to $3931 per course. "While nivolumab substantially improves overall survival in patients with recurrent and metastatic HNC, this therapy is not a cost-effective treatment option at its current cost under a wide array of assumptions," concluded the authors. "While innovations in immunotherapy are promising, we must critically examine the financial and social impact of these therapies on patients and the health care system," they said. * 2017 US dollars Tringale KR, et al. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute : 3 Nov 2017. Available from: URL: http://doi.org/10.1093/jnci/djx226 803284214 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera